Cytek Biosciences to showcase spectral cytometry at ESCCA and ICCS
Cytek Biosciences is attending two major clinical cytometry meetings this autumn to promote its Full Spectrum Profiling (FSP) technology, as the Fremont-based company presses for broader adoption of spectral flow cytometry in clinical research workflows.
The NASDAQ-listed company will exhibit at the European Society for Clinical Cell Analysis (ESCCA) 2026 conference in Salzburg, Austria, running 9 to 12 September, and at the ICCS 41st Annual International Clinical Cytometry Meeting in Miami from 2 to 6 October. At both events, Cytek will host key opinion leader dinners and lead industry sessions.
What Cytek is presenting
The more substantive engagement comes at ESCCA, where Cytek is hosting an industrial partner presentation on 11 September titled "Do We Really Need 40 Colors? Rethinking Spectral Cytometry for Routine Diagnostics and MRD Monitoring." The session will be led by Mikael Roussel, a haematologist from University Hospital Pontchaillou and INSERM U1236, and will address the application of spectral cytometry to minimal residual disease (MRD) monitoring, a clinically important readout in haematological malignancies such as acute leukaemia and multiple myeloma.
At ICCS in Miami, Cytek will host a corporate workshop on 4 October focused on clinical flow cytometry workflows.
Wenbin Jiang, chief executive of Cytek Biosciences, said the company was "seeing new opportunities to expand its use across cell analysis workflows, including MRD research and other translational applications," and framed the conference presence as part of a deliberate push into clinical research settings where laboratories are seeking better efficiency and standardisation.
The company cited more than 4,200 peer-reviewed publications referencing FSP systems as evidence of scientific uptake, though the figure covers research as well as clinical applications and does not distinguish between indication areas.
Market context
Spectral flow cytometry competes with conventional fluorescence-based instruments, and the sector has been growing as multiplexing requirements intensify in immunology and oncology research. Traditional flow cytometry vendors including Beckman Coulter and BD Biosciences have each introduced higher-parameter platforms in recent years, while mass cytometry approaches from companies such as Standard BioTools offer an alternative route to very high-dimensional single-cell analysis.
Cytek's commercial positioning rests on the argument that FSP delivers high-plex capability without the infrastructure and throughput limitations of mass cytometry, making it more accessible for routine clinical laboratory use. MRD monitoring in haematological cancers is a particularly attractive beachhead: regulatory acceptance of MRD as a surrogate endpoint has been advancing at both the FDA and EMA, which could expand the addressable market for clinical-grade cytometry instruments considerably.
The company notes that its products are for research use only in most markets, with clinical diagnostic clearance limited to its Northern Lights system in China and the EU. Widening that regulatory footprint into the United States would represent a meaningful commercial catalyst, though Cytek made no announcement to that effect here.
The conference appearances are promotional rather than data-driven events, and the release contains no new clinical or financial disclosures. Investors and laboratory directors will look to forthcoming publications and the content of Roussel's ESCCA presentation for substantive evidence of FSP's performance in MRD workflows.